CTD2 bridges the gap between the enormous volumes of data generated by genomic characterization studies and the ability to use these data for the development of human cancer therapeutics. It specializes in computational and functional genomics approaches critical for translating next-generation sequencing data.
The CTD2 Network Centers work both independently and collaboratively to advance the understanding of cancer and translate it into improved patient outcomes. Each Center has unique expertise in high-throughput identification and/or characterization of targets for cancer therapy. In-depth mining of large scale genomic data, systems biology analyses, and other experimental approaches are utilized by the Centers to identify functionally significant changes in cancer.
Several Centers also specialize in the identification of small molecules that modulate validated cancer targets for use as probes or therapeutics.
Furthermore, the Network is developing and improving technologies critical for achieving its goals and those of the broader research community.